4 completed, 1 enrolling by invitation, 1 recruiting, 1 unknown. 3 Phase 1, 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Unknown 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 2 | Completed 1, Enrolling by invitation 1 |
Follow Hyundai Pharm: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia Ezetimibe/Rosuvastatin/Candesartan/Amlodipine, Candesartan/Amlodipine, Candesartan/Rosuvastatin/Ezetimibe - Hypertension, Primary Hypercholesterolaemia | Phase 3 | Enrolling by invitation | Hyundai Pharm | 125 | 2025-04-22 | 2025-05-22 |
| To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise HD-6277 100mg, HD-6277 50mg, HD-6277 25mg - Type 2 Diabetes Mellitus (T2DM) | Phase 2 | Recruiting | Hyundai Pharm | 160 | 2024-12-12 | 2024-12-13 |
| To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults Empagliflozin 25 MG, Ezetimibe/Rosuvastatin 10/10mg, Empagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mg - Type 2 Diabetes, Dyslipidemias | Phase 1 | Unknown | Hyundai Pharm | 56 | 2024-06-20 | 2024-08-29 |
| Pharmacokinetics of BPDO-1603 or BPDO-16031 and BPDO-16033 Administration in Healthy Adults BPDO-1603 - Healthy | Phase 1 | Completed | Hyundai Pharm | 24 | 2022-12-28 | 2023-04-07 |
| Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise HD-6277, Placebo - Type 2 Diabetes Mellitus | Phase 2 | Completed | Hyundai Pharm | 112 | 2022-06-17 | 2024-10-18 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LINO-1713 in Healthy Korean Female Subjects LINO-1713 1 tablet, LINO-1713 once a day for 24 days - Contraception | Phase 1 | Completed | Hyundai Pharm | 20 | 2022-01-11 | 2023-01-11 |
| Phase III Study to Evaluate the Efficacy and Safety of HOB-048 CR Tab. in Comparison With HOB-048 Syrup in Patients With Cough Due to Acute or Chronic Bronchitis Levotuss - Evaluate the Efficacy and Safety of Levotuss CR Tab. in Comparison With Levotuss Syrup in Patients With Cough Due to Acute or Chronic Bronchitis | Phase 3 | Completed | Hyundai Pharm | 272 | 2017-01-01 | 2018-11-20 |
Diabetes Mellitus, Type 2 (3) · Alzheimer Disease (1) · Bronchitis, Chronic (1) · Dementia (1) · Dyslipidemias (1) · Hypertension (1)
Ezetimibe (2) · Amlodipine (1) · Rosuvastatin Calcium (1) · candesartan (1) · dipropizine (1) · empagliflozin (1)
South Korea (7)